|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: PIEZO1 |
Gene summary for PIEZO1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | PIEZO1 | Gene ID | 9780 |
| Gene name | piezo type mechanosensitive ion channel component 1 | |
| Gene Alias | DHS | |
| Cytomap | 16q24.3 | |
| Gene Type | protein-coding | GO ID | GO:0006810 | UniProtAcc | Q92508 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 9780 | PIEZO1 | LZE4T | Human | Esophagus | ESCC | 4.68e-04 | 1.02e-01 | 0.0811 |
| 9780 | PIEZO1 | LZE7T | Human | Esophagus | ESCC | 1.19e-04 | 2.06e-01 | 0.0667 |
| 9780 | PIEZO1 | LZE8T | Human | Esophagus | ESCC | 2.46e-04 | 1.51e-01 | 0.067 |
| 9780 | PIEZO1 | LZE20T | Human | Esophagus | ESCC | 1.83e-07 | 1.80e-01 | 0.0662 |
| 9780 | PIEZO1 | LZE22D1 | Human | Esophagus | HGIN | 8.17e-03 | 1.03e-01 | 0.0595 |
| 9780 | PIEZO1 | LZE22T | Human | Esophagus | ESCC | 1.00e-04 | 4.06e-01 | 0.068 |
| 9780 | PIEZO1 | LZE24T | Human | Esophagus | ESCC | 2.43e-06 | 1.59e-01 | 0.0596 |
| 9780 | PIEZO1 | LZE21T | Human | Esophagus | ESCC | 8.50e-03 | 2.84e-01 | 0.0655 |
| 9780 | PIEZO1 | P1T-E | Human | Esophagus | ESCC | 2.02e-08 | 5.39e-01 | 0.0875 |
| 9780 | PIEZO1 | P2T-E | Human | Esophagus | ESCC | 1.35e-13 | 1.03e-01 | 0.1177 |
| 9780 | PIEZO1 | P4T-E | Human | Esophagus | ESCC | 4.90e-08 | 9.63e-02 | 0.1323 |
| 9780 | PIEZO1 | P5T-E | Human | Esophagus | ESCC | 3.31e-16 | 2.19e-01 | 0.1327 |
| 9780 | PIEZO1 | P8T-E | Human | Esophagus | ESCC | 3.05e-12 | 3.26e-01 | 0.0889 |
| 9780 | PIEZO1 | P9T-E | Human | Esophagus | ESCC | 1.58e-10 | 6.85e-02 | 0.1131 |
| 9780 | PIEZO1 | P10T-E | Human | Esophagus | ESCC | 7.61e-10 | 1.68e-01 | 0.116 |
| 9780 | PIEZO1 | P11T-E | Human | Esophagus | ESCC | 6.33e-11 | 3.55e-01 | 0.1426 |
| 9780 | PIEZO1 | P12T-E | Human | Esophagus | ESCC | 2.24e-08 | 1.40e-01 | 0.1122 |
| 9780 | PIEZO1 | P15T-E | Human | Esophagus | ESCC | 3.43e-07 | 1.54e-01 | 0.1149 |
| 9780 | PIEZO1 | P16T-E | Human | Esophagus | ESCC | 2.62e-07 | 6.05e-02 | 0.1153 |
| 9780 | PIEZO1 | P17T-E | Human | Esophagus | ESCC | 1.20e-11 | 4.36e-01 | 0.1278 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:003133425 | Esophagus | HGIN | positive regulation of protein-containing complex assembly | 61/2587 | 237/18723 | 7.10e-07 | 3.00e-05 | 61 |
| GO:004325427 | Esophagus | HGIN | regulation of protein-containing complex assembly | 94/2587 | 428/18723 | 2.39e-06 | 8.55e-05 | 94 |
| GO:007149626 | Esophagus | HGIN | cellular response to external stimulus | 71/2587 | 320/18723 | 2.77e-05 | 7.19e-04 | 71 |
| GO:007121418 | Esophagus | HGIN | cellular response to abiotic stimulus | 66/2587 | 331/18723 | 1.21e-03 | 1.45e-02 | 66 |
| GO:010400418 | Esophagus | HGIN | cellular response to environmental stimulus | 66/2587 | 331/18723 | 1.21e-03 | 1.45e-02 | 66 |
| GO:0043254111 | Esophagus | ESCC | regulation of protein-containing complex assembly | 278/8552 | 428/18723 | 3.81e-16 | 2.77e-14 | 278 |
| GO:0071496111 | Esophagus | ESCC | cellular response to external stimulus | 215/8552 | 320/18723 | 4.29e-15 | 2.43e-13 | 215 |
| GO:0031334111 | Esophagus | ESCC | positive regulation of protein-containing complex assembly | 166/8552 | 237/18723 | 2.06e-14 | 1.07e-12 | 166 |
| GO:007121419 | Esophagus | ESCC | cellular response to abiotic stimulus | 206/8552 | 331/18723 | 7.52e-10 | 1.88e-08 | 206 |
| GO:010400419 | Esophagus | ESCC | cellular response to environmental stimulus | 206/8552 | 331/18723 | 7.52e-10 | 1.88e-08 | 206 |
| GO:004578527 | Esophagus | ESCC | positive regulation of cell adhesion | 255/8552 | 437/18723 | 5.07e-08 | 9.11e-07 | 255 |
| GO:00712606 | Esophagus | ESCC | cellular response to mechanical stimulus | 54/8552 | 81/18723 | 1.09e-04 | 7.64e-04 | 54 |
| GO:000961216 | Esophagus | ESCC | response to mechanical stimulus | 124/8552 | 216/18723 | 3.30e-04 | 1.94e-03 | 124 |
| GO:002240720 | Esophagus | ESCC | regulation of cell-cell adhesion | 239/8552 | 448/18723 | 5.88e-04 | 3.19e-03 | 239 |
| GO:002240919 | Esophagus | ESCC | positive regulation of cell-cell adhesion | 155/8552 | 284/18723 | 1.50e-03 | 7.06e-03 | 155 |
| GO:00336275 | Esophagus | ESCC | cell adhesion mediated by integrin | 45/8552 | 72/18723 | 2.97e-03 | 1.24e-02 | 45 |
| GO:00336281 | Esophagus | ESCC | regulation of cell adhesion mediated by integrin | 31/8552 | 48/18723 | 6.41e-03 | 2.35e-02 | 31 |
| GO:004325412 | Liver | Cirrhotic | regulation of protein-containing complex assembly | 169/4634 | 428/18723 | 7.40e-12 | 4.99e-10 | 169 |
| GO:007149612 | Liver | Cirrhotic | cellular response to external stimulus | 123/4634 | 320/18723 | 3.27e-08 | 1.10e-06 | 123 |
| GO:00313347 | Liver | Cirrhotic | positive regulation of protein-containing complex assembly | 95/4634 | 237/18723 | 1.21e-07 | 3.39e-06 | 95 |
| Page: 1 2 3 4 5 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| PIEZO1 | SNV | Missense_Mutation | novel | c.2108N>A | p.Arg703Lys | p.R703K | Q92508 | protein_coding | tolerated(0.78) | benign(0.001) | TCGA-A2-A0CR-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | CR |
| PIEZO1 | SNV | Missense_Mutation | c.6790N>C | p.Asp2264His | p.D2264H | Q92508 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| PIEZO1 | SNV | Missense_Mutation | rs34873950 | c.4316N>T | p.Ser1439Leu | p.S1439L | Q92508 | protein_coding | tolerated(0.27) | benign(0.003) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
| PIEZO1 | SNV | Missense_Mutation | c.1505N>A | p.Arg502His | p.R502H | Q92508 | protein_coding | tolerated(0.19) | benign(0) | TCGA-AC-A2FB-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | taxotere | CR | |
| PIEZO1 | SNV | Missense_Mutation | c.4724C>T | p.Ala1575Val | p.A1575V | Q92508 | protein_coding | tolerated(0.3) | benign(0.003) | TCGA-BH-A18G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| PIEZO1 | SNV | Missense_Mutation | novel | c.5587C>A | p.Pro1863Thr | p.P1863T | Q92508 | protein_coding | tolerated(0.15) | benign(0.015) | TCGA-D8-A27M-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | methotrexate+5 | SD |
| PIEZO1 | SNV | Missense_Mutation | novel | c.503C>G | p.Ala168Gly | p.A168G | Q92508 | protein_coding | tolerated(0.42) | benign(0) | TCGA-E9-A22G-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
| PIEZO1 | SNV | Missense_Mutation | c.1513N>C | p.Gly505Arg | p.G505R | Q92508 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-GM-A2DO-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | CR | |
| PIEZO1 | SNV | Missense_Mutation | novel | c.7219N>A | p.Glu2407Lys | p.E2407K | Q92508 | protein_coding | tolerated(0.25) | benign(0.043) | TCGA-UL-AAZ6-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | herceptin | SD |
| PIEZO1 | SNV | Missense_Mutation | novel | c.4118G>A | p.Arg1373His | p.R1373H | Q92508 | protein_coding | tolerated(0.2) | benign(0) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 9780 | PIEZO1 | ION CHANNEL, TRANSPORTER | inhibitor | 381118822 | ||
| 9780 | PIEZO1 | ION CHANNEL, TRANSPORTER | activator | 354702289 |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |